NCT04621227View on ClinicalTrials.gov

Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 15, 2020

Primary Completion Date

May 13, 2021

Study Completion Date

May 13, 2021

Conditions
Obesity
Interventions
DRUG

PF-06882961

120 mg and 200 mg BID

DRUG

Rosuvastatin

10 mg single dose

DRUG

Midazolam

2mg single dose

Trial Locations (1)

92801

Anaheim Clinical Trials, LLC, Anaheim

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04621227 - Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity | Biotech Hunter | Biotech Hunter